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RESEARCH
Peer support for patients with type 2 diabetes: cluster
randomised controlled trial
S M Smith, senior lecturer in primary care,1 G Paul, research project manager,1 A Kelly, senior lecturer in
biomedical statistics,1 D L Whitford, professor of family and community medicine,2 E O’Shea, professor of
economics,3 T O’Dowd, professor of general practice1
ABSTRACT
Objective To test the effectiveness of peer support for
patients with type 2 diabetes.
Design Cluster randomised controlled.
Setting 20 general practices in the east of the Republic of
Ireland.
Participants 395 patients (192 in intervention group, 203
in control group) and 29 peer supporters with type 2
diabetes.
Intervention All practices introduced a standardised
diabetes care system. The peer support intervention ran
over a two year period and contained four elements: the
recruitment and training of peer supporters, nine group
meetings led by peer supporters in participant’s own
general practice, and a retention plan for the peer
supporters.
Main outcome measures HbA1c; cholesterol
concentration; systolic blood pressure; and wellbeing
score.
Results Therewas no difference between intervention and
control patients at baseline. All practices and 85% (337)
of patients were followed up. At two year follow-up, there
were no significant differences in HbA1c (mean difference
−0.08%, 95% confidence interval −0.35% to 0.18%),
systolic blood pressure (−3.9mmHg, −8.9 to 1.1mmHg),
total cholesterol concentration (−0.03 mmol/L, −0.28 to
0.22 mmol/L), or wellbeing scores (−0.7, −2.3 to 0.8).
While there was a trend towards decreases in the
proportion of patients with poorly controlled risk factors
at follow-up, particularly for systolic blood pressure (52%
(87/166) >130 mm Hg in intervention v 61% (103/169)
>130 mm Hg in control), these changes were not
significant. The process evaluation indicated that the
intervention was generally delivered as intended, though
18% (35) of patients in the intervention group never
attended any group meetings.
Conclusions A group based peer support intervention is
feasible in general practice settings, but the intervention
was not effective when targeted at all patients with type 2
diabetes. While there was a trend towards improvements
of clinical outcomes, the results do not support the
widespread adoption of peer support.
Trial registration Current Controlled Trials
ISRCTN42541690.
INTRODUCTION
There has been an increasing focus on involvement of
patients in chronic disease care, and theWorld Health
Organization’s action plan for chronic disease man-
agement encourages governments to take action to
help people manage their own chronic conditions bet-
ter by providing education, incentives, and tools for
self management and care.1 Type 2 diabetes is a
chronic disease that is rising in prevalence across the
world and placing increasing demands on healthcare
systems. WHO has suggested that peer support is a
promising approach for diabetes care as it harnesses
the ability of patients with diabetes to support each
other in managing their everyday lives.2 Peer support
has been defined as the provision of support from an
individual with experiential knowledge based on a
sharing of similar life experiences.3 It is usually pro-
vided within a volunteering framework and can be
delivered inmany ways, including group or individual
support or through more remote formats such as tele-
phone or internet based support.
Peer support has been used in various conditions
with varied results,4-10 but there is limited evidence to
support its effectiveness, particularly for people with
type 2 diabetes. There is also substantial variation in
the degree of training and level of involvement of the
peer supporters or community health workers in these
studies, with many having a predominantly educa-
tional focus and peer groups being facilitated by health
professionals rather than peers themselves.10
We report the results of a pragmatic cluster rando-
mised controlled trial examining the effectiveness of
peer support in improving biophysical and psychoso-
cial outcomes for people with type 2 diabetes. The
intervention was based on social support theory and
was delivered in groups based in the general practices
of participating patients.
METHODS
The methods and intervention development have
been reported in detail previously.11 12 In brief, this
was a cluster randomised controlled trial set in general
practices in the Republic of Ireland. Diabetes care in
Ireland has generally been unstructured, with more
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than half of patients still attending specialist diabetes
clinics for annual reviews.13 Thirty two practices from
the Trinity College Dublin network of teaching prac-
tices were invited to participate, and 20 accepted. Prac-
tices were eligible to participate if they had a practice
nurse; had computerised records; did not participate in
the pilot study; had a minimum of about 1000 patients
with GMS cards (eligible for free healthcare) or had
more than 50 patients on their register of those with
type 2 diabetes, or both; and were not participating in
an existing shared care diabetes programme involving
structured care between the general practices and hos-
pital diabetes clinics. Participating practiceswere given
a grant of €5000 (£4200, $6900) a year for three years.
This grant reflected the fact that data collection and
intervention delivery were carried out at practice
level with the support of the research team.
Practices were stratified by practice size and the pre-
sence of existing structured diabetes care and were
then allocated to control or intervention group by an
independent statistician using minimisation.14 All
practices introduced a structured diabetes care system
as only two of them had such systems in place before
the study. This involved regular recall of patients every
three to six months with an annual audit of risk factors.
This was done to standardise delivery of diabetes care
across all study practices so that the peer support inter-
ventionwould be an addition to diabetes care.All prac-
tices created or, in the case of two practices, updated
their diabetes registers. Intervention practices then
recruited three individuals as peer supporters.
The box outlines the eligibility criteria for peer sup-
porters. They attended two evening training sessions
each lasting about 90 minutes and delivered by the
research team. Appendix 1 on bmj.com describes the
content of the training sessions. Peer supporters were
advised that they were not being asked to provide
healthcare or education and that the emphasis was on
social support. Therewas also a strong emphasis on the
importance of confidentiality, and peer supporters
were given specific advice as to how they could seek
support from their general practitioner and practice
nurse or the study manager if needed. The general
practitioners and practice nurses also received training
in relation to the studyprotocol anddelivering standar-
dised diabetes care (one author (SMS) delivered a
90 minute session in each practice with an academic
detailing approach). Further details of the training are
provided in the study protocol.12
We used a randomnumber list to select patients ran-
domly from the practice diabetes register until a total of
21 patients were recruited in each practice. To be eligi-
ble patients had to be aged over 18, have type 2 dia-
betes, be able to participate in a group, and be
attending one of the participating practices. Those
who agreed to participate were invited to attend their
practice to complete a questionnaire containing demo-
graphic information and study outcomemeasures. The
practice nurse then collected biophysical outcome
data.
The intervention was developed with the MRC Fra-
mework for the evaluation of complex interventions to
improve health.15 The underlying theoretical frame-
work was social support, and the full development of
the intervention has been described in detail
previously.11 The intervention was delivered over a
two year period, from May 2007 to April 2009. The
box describes the components of the intervention.
The primary outcomes were HbA1c (measured with
reversed phase cation exchange liquid chromatogra-
phy, with an automatic glycol-haemoglobin analyser,
DCCT compatible); blood pressure (measuredwith an
OMRON M5-1 Automatic BP monitor); cholesterol
concentration (analysed in local hospital laboratories
with automated clinical chemistry analysers), and
wellbeing.16 Secondary outcomes were body mass
index (BMI), diabetes self care activities,17 self
efficacy,18 adherence to medications,19 family and
friends subscale of the chronic illness resources
survey,20 smoking (self reported), prescriptions
(aspirin, antihypertensive drugs, and cholesterol low-
ering agents), andmeasures of the process of care (visits
The peer support intervention
The peer support intervention had the following components:
Peer supporters
Peer supporters were identified by general practitioners and practice nurses and were
trained at a ratio of about one peer supporter to seven or eight patients with type 2
diabetes. The criteria for eligibility were:
 Having had type 2 diabetes for at least one year
 Participation in preventive treatments and judged by the practice team as being
generally adherent to treatment and behaviour change regimens
 Capacity and commitment to undergo the training required
 A full understanding of the importance of patients’ confidentiality
 Undertaking to liaise with the practice nurse or general practitioner if unanticipated
problems arose during the course of their peer support activity
Peer supporter training
The peer supporters attended two evening training sessions, which were conducted by the
research team. These sessions focused on the basics of type 2 diabetes and issues
relating to working with groups and confidentiality.
Peer support meetings
Peer support meetings were held in the general practice premises at a convenient time for
practice staff, peer supporters, and participants. Practices offered various daytime or early
evening sessions, depending on patients’ preference. There were nine peer support
sessions over two years; at month one, month two, and every three months thereafter.
Each meeting was facilitated by the peer supporter, and there were no health
professionals present in the meeting room though they were available on site, if needed.
Each meeting had a suggested theme and a small structured component. The contents of
the meetings were recorded (see appendix 2 on bmj.com). There was also a “frequently
asked questions” (FAQs) system—that is, at the end of each session the group fed back
questions to the research team who compiled written answers based on the feedback
from all groups. The FAQs from all groups were combined and sent back to the groups for
the next session.
Retention and support of peer supporters
Formal structures were put in place to ensure peer support workers were supported in their
role, including telephone calls from the project manager before and after meetings; a
course handbook and resource pack; an annual social or educational event; a protocol to
follow if a peer supporter resigned; and travel and related expenses (this was given in the
form of a general shopping voucher at the end of each year with a value of €300).
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to general practitioner, practice nurse, hospital dia-
betes outpatients department, and hospital diabetes
centre and admissions to hospital). Demographic
details, including measures of socioeconomic status
(medical card status) and educational attainment,
were also collected. Participants completed the ques-
tionnaire while waiting to see the practice nurse, who
then checked that the questionnaire was filled in and
completed the biophysicalmeasures. The nurses extra-
cted data relating to the process of care from the
patients’ records and entered all data into a FileMaker
Pro database.21 The project manager doubled checked
the data. Full details of data collection and storage pro-
cedures are outlined in the study protocol.12 We could
not blind participants or practice nurses collecting data
to group allocation because of the nature of the inter-
vention. Three of the four primary outcomes, how-
ever, were collected with automated tests.
We undertook a process evaluation of the trial and
measured treatment fidelity using a framework devel-
oped by Bellg et al.22 This involved consideration of
five elements: treatment design, training procedures,
delivery of treatment, receipt of treatment, and enact-
ment of treatment skills. This information was col-
lected with peer supporter log diaries, the study
managers’ contact records, and focus groupswith prac-
tice staff, peer supporters, and participants. Parallel
qualitative and economic analyses are ongoing and
will be reported elsewhere.
Sample size calculation
We aimed to achieve a sample of 400 patients from 20
practices. This incorporated the effect of cluster rando-
misation and allowed for 80-85% follow-up of patients
and a 15% rate of practice attrition. Sample size calcu-
lations also incorporated a 20% improvement from
Intervention practices (n=10)Control practices (n=10)
General practices (n=32)
Total follow-up
Practices (n=20/20, 100%)
 Participants (n=337/395, 85%)
General practices (n=20)
Patients on diabetes register (n=853)Patients on diabetes register (n=864)
Randomly selected (n=365)Randomly selected (n=292)
Participants recruited (n=203) Participants recruited (n=192)
Control practices followed up
(n=10/10, 100%)
Intervention practices followed up
(n=10/10, 100%)
Control participants
followed up
(n=171/203, 84%)
Intervention participants
followed up
(n=166/192, 87%)
Declined (n=89):
  Not interested (n=36)
  No reason (n=29)
  Too old/frail (n=8)
  Too busy (n=4)
  Satisified with current care
    (n=3)
  Other (n=9)
Declined (n=173):
  Not interested (n=125)
  No reason (n=30)
  Too old/frail (n=6)
  Too busy (n=4)
  Satisified with current care
    (n=2)
  Other (n=6)
Did not attend intervention (n=34/192, 18%)*:
  Not interested (n=14)
  Time not suitable/too busy (n=8)
  Family bereavement (n=3)
  Caring for a sick relative (n=2)
  Travels regularly (n=2)
  Cancer diagnosis (n=1)
  No specific reason (n=1)
  Embarrassed about illness (n=1)
  Difficulty hearing in a group (n=1)
  Lives to far from practice (n=1)
Lost to follow-up (n=26/221, 12%):
  Died (n=9)
  Moved practice (n=4)
  In hospital (n=2)
  Dropped out (n=11)
Lost to follow-up (n=32/203, 16%):
  Died (n=6)
  Moved practice (n=8)
  In hospital (n=5)
  Dropped out (n=13)
Declined (n=12):
  Not interested/too busy (n=10)
  Involved in another study (n=1)
  Involved in shared care (n=1)
Recruitment and follow-up of practices and participants. *Does not include participants lost to follow-up
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baseline in the control group and 50% improvement in
the intervention group. All calculations were two sided
and based on an α of 5% and a power of 80%. Full
details are reported in the study protocol.12
HbA1c—Weneeded 130 patients fromeight practices
to show a clinically significant difference in mean
HbA1c between intervention and control groups (that
is, a difference of 0.9%23; SD 1.6, intracluster coeffi-
cient 0.00124).
Systolic blood pressure—We needed 400 patients from
20 practices to show a significant improvement in the
proportion of patients with a systolic blood pressure
below 160 mm Hg. This was in the context of a treat-
ment target of 135mmHg,25 based on locally available
data indicating that 46% of patients in a previous study
in Dublin had a systolic blood pressure >160 mm Hg
and the intracluster coefficient was 0.001.24
Cholesterol—We needed 410 patients from 20 prac-
tices to show a significant improvement in the propor-
tion of patients with a cholesterol concentration
<5 mol/L, which was the treatment target for choles-
terol at that time.25 Locally available data indicated that
57% of patients had a concentration >5 mmol/L and
the intracluster coefficient was 0.06.10
Wellbeing scores—We needed 221 patients from 12
practices to show a clinically significant difference in
wellbeing scores between intervention and control
groups (that is, a mean difference of 5 points, SD
10.3; intracluster coefficient 0.0724).
Statistical analysis
The analyses were based on intention to treat and are
reported according to the CONSORT guidelines for
the reporting of cluster randomised controlled trials.26
We also undertook a sensitivity analysis and a per pro-
tocol analysis to estimate the effect of exposure to the
intervention or group attendance on outcomes. Pre-
planned analyses were also conducted to examine
those participants whose risk factors were above target
ranges at baseline—that is, HbA1c >7%, systolic blood
pressure >130 mm Hg, and cholesterol concentration
>4.8 mmol/L. These were the targets presented to the
clinicians involved in delivering diabetes care across
both intervention and control practices.
Weusedmultilevel linear or logistic regressionmod-
els with random effects of patients nested within prac-
tices. In these models, the primary fixed effect of
interest is the differential effect of intervention versus
control over time. For the subgroup analysis, we
selected individuals deemed out of control at baseline
for modelling with practice as a random effect. The
effect size in this instance refers to the contrast between
the intervention versus the control group at follow-up.
For all models, we included additional patient specific
(such as age and sex) and practice specific (such as type
of practice) covariates. The multilevel analysis was
conducted with R (2.11).27
Analysis of secondary outcomes was limited to an
intention to treat cluster level analysis apart from ana-
lysis of BMI, which achieved a significant effect in this
preliminary analysis sowas then entered into themulti-
level model analysis.
RESULTS
The figure shows the flow of practices and patients
through the study. We could not carry out baseline
data collection before randomisation of practices as
we had to first identify intervention practices so that
we could recruit and train the peer supporters, which
took place over a six month period. As a result, there
was a difference in recruitment rates of patients
between intervention and control practice. More
potential participants had to be invited to participate
in the study in intervention practices. Recruitment of
participants took place between November 2006 and
April 2007 and the intervention ran from May 2007
until April 2009. Non-participants in both the inter-
vention and control practices were similar in terms of
sex, age, and socioeconomic status (as measured by
Table 1 | Baseline characteristics of participants with type 2 diabetes allocated to peer
support (intervention) or no peer support (control) and peer supporters. Figures are numbers
(percentage) of participants unless stated otherwise
Intervention
group (n=192)
Control group
(n=203)
Peer supporters
(n=29)
Practice factors at baseline
No of practices 10 10 —
Mean No of patients/practice 4830 5800 —
Urban location 8 8 —
Mean % of practice population on diabetes
register
1.7% 1.7% —
Diabetes care*:
GP only 68 (35) 60 (30) —
GP and specialist 60 (30) 73 (36) —
Specialist only 62 (32) 65 (32) —
No care 3 (2) 5 (2) —
Participants and peer supporters
Women 88 (46) 93 (46) 17 (59)
Mean (SD) age (years) (n=424) 66.1 (11.11) 63.2 (11.04) 62.7 (11.3)
Mean (SD) duration of diabetes (years) (n=418) 7.4 (7) 6.9 (6.3) 6.8 (8.1)
GMS card† 92 (48) 108 (53) 8 (30)
Education status:
Primary education only 79 (41) 98 (48) 5 (17)
Complete third level education 15 (8) 10 (5) 9 (31)
Self reported smoking 31 (16) 40 (20) 4 (14)
Diabetes regimen:
Diet controlled 52 (27) 38 (19) 9 (31)
Oral hypoglycaemic drugs 133 (69) 160 (79) 14 (48)
Insulin 5 (3) 3 (1) 2 (7)
Missing 2 (1) 2 (1) 4 (14)
Marital status:
Married/cohabiting 134 (68) 113 (59) 20 (70)
Single, widowed, separated, divorced 65 (33) 79 (41) 9 (30)
Missing 2 (0.5) 0 (0) 0 (0)
≥3 medical conditions 134 (70) 129 (64) 27 (93)
*According to patient.
†Eligibility for GMS (general medical services) card implies being in 30% of population with lowest income and
indicates eligibility for free healthcare.
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eligibility for free primary health care). Follow-up data
collection took place between May and June 2009.
Table 1 gives the characteristics of patients in the
intervention and control group and the peer suppor-
ters. Tables 2 and 3 present the primary and secondary
outcomes. They indicate better than anticipated con-
trol of risk factors at baseline, though a considerable
proportion of patients still had risk factors above target
levels. Of the participants, 163/388 (42%) had an
HbA1c above 7%; 291/394 (74%) had a systolic blood
pressure above 130 mm Hg, and 89/387 (23%) had a
total cholesterol concentration above 4.8 mmol/L.
These treatment targets for risk factors differed from
those used for the original power calculation as there
had been changes in the target levels in the intervening
years.
Follow-up results
At follow-up we found no significant improvements in
any primary or secondary outcomes when we used
multi-level modelling that accounted for clustering
and other confounding variables (see tables 2 and 3).
We also carried out multi-level modelling to examine
the subgroups of patients with poorly controlled risk
factors at baseline, and,while therewas a trend towards
clinically relevant improvements in proportions with
better blood pressure control, these effects were not
significant (table 4).
We carried out additional per protocol analyses as
planned to test whether there were any links between
group attendance and outcomes. We found nothing
relating to attendance versus non-attendance and to
numbers of groups attended by participants that
could be regarded as a dose effect.
Peer supporters
At baseline data from peer supporters and participants
were similar (table 1), though peer supporters had
attained a higher level of education. Primary outcomes
at baseline for the peer supporters were mean HbA1c
6.8%, mean total cholesterol 4.3 mmol/L, mean systo-
lic blood pressure 140 mm Hg, and mean wellbeing
score 27. Primary outcomes at follow-up were mean
HbA1c 6.9%, mean total cholesterol 3.7 mmol/L,
mean systolic blood pressure 139 mm Hg, and mean
wellbeing score 24. Secondary outcomes at baseline
and follow-up were also similar in peer supporters
and participants. Twenty nine (97%) peer supporters
were followed up. The descriptive analysis of the peer
supporters at follow-up indicated no significant
changes over time apart from some decline in well-
being (mean score 27 at baseline; 24.1 at follow-up).
Process evaluation
The training and intervention were delivered as
planned for the general practitioners, practice nurses,
and peer supporters in the protocol. All intervention
and control practices implemented structured diabetes
care as planned. All the practices and 28 out of the 29
peer supporters were followed up, though only 23 of
the peer supporters were retained in their role. The
main concern regarding the delivery and receipt of
treatment—that is, the intervention—was the low
attendance at the group meetings. Participants in the
intervention group attended a mean of five peer sup-
port meetings, and 18% never attended a meeting and
therefore had no exposure to the intervention. This
was despite repeated phone calls from practice nurses
and a call from the study manager to all non-attenders
after the third round of meetings.
Peer supporters were contacted after each meeting
and also kept diaries. Appendix 2 on bmj.com pro-
vides data collected about the content of peer support
meetings. In general, the groups followed and dis-
cussed the planned topics.
The process evaluation also highlighted the heavy
workload involved in delivering a peer support inter-
vention over two years. There was a mean of 15 con-
tacts between the study manager and the intervention
practices relating specifically to the peer support inter-
vention rather than the research process. There was a
mean of 25 contacts with the peer supporters during
the two year period. These contacts included training
sessions, meetings, telephone calls, and letters and
indicate that as an intervention peer support requires
substantial clinical and administrative input. Most of
these contacts related to running the intervention
rather than collection of research data.
DISCUSSION
For people with diabetes a group based peer support
intervention is feasible in general practice settings.
While there was a trend towards improved manage-
ment of clinical risk factors, however, peer support
did not significantly improve physical and psychoso-
cial outcomes for people with type 2 diabetes. One
Table 2 | Primary outcomes at baseline and follow-up in participants with type 2 diabetes allocated to peer support (intervention) or no peer support
(control)
No of people (baseline/
follow-up)
Mean (SD) outcome
at baseline
Mean (SD) outcome
at follow-up
ICC Meandifference (95%CI) P valueIntervention Control Intervention Control Intervention Control
HbA1c (%) 187/165 201/170 7.2 (1.4) 7.2 (1.2) 7.1 (1.1) 7.1 (1.2) 0.005 −0.08 (−0.35 to 0.18) 0.64
Systolic bloodpressure (mmHg) 192/166 202/169 146 (21) 144 (18) 136 (19) 137 (15) 0.007 −3.9 (−8.9 to 1.1) 0.12
Cholesterol (mmol/L) 186/164 201/170 4.1 (0.9) 4.5 (1.2) 3.9 (0.9) 4.3 (0.9) 0.004 −0.03 (−0.28 to 0.22) 0.81
Wellbeing score* 192/147 201/157 25.0 (6.8) 23.9 (7.6) 23.7 (5.1) 23.2 (5.8) 0.0001 −0.71 (−2.3 to 0.8) 0.36
ICC=intracluster coefficient.
*Range 0-36 (1-12 low, 13-24 medium, 25-36 high).
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explanation for this is that, despite the hope that peers
could be harnessed to improve outcomes for patients,
peer support is ineffective when delivered as a struc-
tured intervention. There are some features of this
study, however, that suggest we do not yet have a defi-
nitive answer about the potential effectiveness of peer
support in type 2 diabetes. In particular, while the
study achieved its proposed sample size, baseline
levels of risk factors for diabetes had improved in the
intervening years, leaving little room for improvement
in mean HbA1c, systolic blood pressure, and total cho-
lesterol concentration. The treatment targets had also
changed, however, becoming tighter over time, and
there were still significant proportions of patients not
meeting these targets, particularly for systolic blood
pressure.
Secondary outcomemeasures were also no different
between intervention and control groups. These indi-
cated high levels of adherence to treatment drugs and
self efficacy and medium level scores for diabetes self
care activities and social support at baseline and follow-
up. The intervention might not have been intensive
enough to affect broader outcomes. We were, how-
ever, trying to achieve a balance between overburden-
ing the peer supporters with frequent meetings and
having sufficient exposure to the intervention in
terms of meeting intensity.
There was a non-significant reduction in wellbeing
in the intervention group, and, while this is also clini-
cally relevant, it is important to consider that peer sup-
port could have a detrimental impact on wellbeing if
groups focused on negative experiences. In relation to
social support, it was difficult to find a measure that
reflected the type of social support that a group based
intervention might provide. The measure used might
have failed to detect the type of social support that
peers provide compared with the support provided
by family and friends, which existing measures
consider. This is possible as the qualitative analysis
indicated that participants valued the meetings and
were positive about the support they had received
from their leaders and fellow group members
(G Paul, personal communication). An alternative
social support outcomemeasure would be the Lubben
social network scale.28 While this scale does focus on
broader social, less disease oriented social support net-
works, it has been used only in older patients.
Comparison with other studies
Our results are consistent with those of other studies
published on peer support for type 2 diabetes, which
have also failed, in general, to showa significant impact
on glycaemic control as measured by HbA1c.9 10 29-32
Lorig et al recently published a randomised controlled
trial of their chronic disease self management pro-
gramme adapted for people with diabetes.9 While
they found improvements in depression and in healthy
eating, there was no effect on HbA1c. Studies examin-
ing peer support have not specifically targeted patients
with poorly controlled type 2 diabetes, and such
patients might benefit most from a peer support inter-
vention. Our qualitative analysis also indicated that
participants thought they would have benefited from
peer support around the time of diagnosis (G Paul, per-
sonal communication). The logistics of running a trial
of a peer support intervention for people with a new
diagnosis would be more challenging but perhaps
worth pursuing.
While most of the studies of peer support for type 2
diabetes to date have shown no benefit for participants
in terms of glycaemic control, benefits in terms of per-
sonal gains (training and satisfaction of helping people)
for peer supporters have been reported.33 In this study,
however, the peer supporters showed some decline in
wellbeing at follow-up, though this might be a chance
finding as numbers were small. This raises concerns
Table 3 | Secondary outcomes at baseline and follow-up in participants with type 2 diabetes allocated to peer support
(intervention) or no peer support (control). Figures are mean (SD) scores except where indicated
Variable
No of people
(baseline/follow-up) Outcome at baseline Outcome at follow-up Mean
difference PvalueIntervention Control Intervention Control Intervention Control
BMI 191/164 200/168 30.3 (1.5) 31.8 (1.2) 30.3 (1.5) 31.7 (1.1) 1.4 0.56*
MARS score† 184/157 197/163 23.9 (1.7) 23.8 (1.8) 24.1 (0.3) 23.9 (0.4) 0.2 0.13
Social support score‡ 192/148 199/152 23.8 (9.2) 22.4 (8.4) 23.6 (2) 23 (4.3) 0.6 0.7
DMSES§ 191/146 201/137 119 (26.6) 112 (26.5) 117.1 (12.1) 117.5 (8.1) −0.4 0.9
SDSCA score¶:
General diet
192/154 201/156
5.1 (2.1) 4.7 (2.1) 5.1 (1.8) 5.2 (1.8) −0.1 0.9
Specific diet 4.2 (1.8) 4.1 (1.7) 4.3 (1.5) 4.1 (1.5) 0.2 0.3
Foot care 2.7 (2.4) 2.7 (2.4) 3 (2.5) 2.9 (2.2) 0.1 0.5
Exercise 3 (2.5) 2.7 (2.3) 3.3 (2.2) 3.5 (2.5) −0.2 0.8
Blood glucose testing 4.8 (2.7) 4 (2.9) 4.9 (2.6) 4.3 (2.9) 0.6 0.1
No (%) who self reported
smoking
186/161 202/168 31 (16) 40 (20) 25 (15.5) 29 (17) 1.5% 0.7
*Adjusted with multilevel modelling as P=0.03 in simple cluster level analysis.
†Medication adherence score, range 5-25, higher scores=better adherence.
‡Range 8-40, higher scores=more social support experienced.
§Diabetes management self efficacy scale, range 0-150 (<50 low, 50-100 medium, 100-150 high).
¶Summary of self care activities score, range 0-7, higher score=higher level of self care.
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that the role of peer supporter could be demanding and
stressful for the peer supporters themselves, particu-
larly if participants fail to attend group meetings. This
has been described previously in other peer support
settings.34
Strengths and limitations
This cluster randomised controlled trial of group peer
support for patients with type 2 diabetes included
detailed analysis of the peer supporters as well as parti-
cipants. Follow-up of practices and participants was
high, and there was clearly defined structured diabetes
care across both intervention and control practices so
that changes in diabetes care could not have been
attributed to differences in healthcare delivery as we
were trying to assess the potential effectiveness of the
peer support intervention itself. A full process evalua-
tion was carried out that indicated the interventionwas
largely delivered as planned. It also highlighted the
considerable workload involved in supporting the
intervention. Thedifferential recruitment rate between
intervention and control practices and the lower than
expected attendance rates indicate that group based
peer support is not attractive to all patients with type
2 diabetes and reduced the external validity of this
study.35 Other modes of provision of peer support
might need to be offered in parallel with group meet-
ings. It might also be important to consider flexible
approaches to providing peer support, such as having
drop-in groups available when patients need support
rather than providing scheduled courses that take no
account of individual needs.36 Other issues relating to
external generalisability include resourcing of prac-
tices. We provided a grant to practices to recognise
the work involved in setting up peer support groups
and providing ongoing informal support to the peer
supporters. The workload of the study manager was
considerable and that role is essential to the running
of a peer support intervention and needs to be consid-
ered if peer support is to be introduced on a larger
scale.
One limitation was our inability to conceal alloca-
tion. Practices had to be randomised before we col-
lected baseline data so that peer supporters could be
identified and trained in intervention practices. This
reduced the internal validity of the study as did the
lack of blinding of outcome data. Practice nurses col-
lected outcome data and so were not blind to group
allocation. For three of the four primary outcomes,
however, data were collected with automated tests or
devices so thisminimised the risk of detectionbias. The
study performedwell in relation to the other features of
internal validity for cluster randomised trials described
by Eldridge et al.35 A further potential limitation is that
the presence of a peer support intervention within a
practice could have motivated the entire team to pro-
vide better diabetes care. The process evaluation and
the data relating to prescribing, however, did not sug-
gest differences in delivery of diabetes care between
intervention and control practices.
Conclusion
This cluster randomised controlled trial indicates that
it is feasible to implement a peer support system for
patients with type 2 diabetes attending general prac-
tices, though not all patients will be interested in parti-
cipating. The intervention was not effective in
improving biophysical and psychosocial outcomes
for individuals with type 2 diabetes, when targeted at
all such patients. While there was a trend towards
improvements of clinical outcomes, particularly for
systolic blood pressure, our results suggest that peer
support should not be widely adopted in clinical prac-
tice until further research is carried out. The Peers for
Progress organisation is currently carrying out several
trials and demonstration projects of peer support for
type 2 diabetes across the world.37 Future research
could focuson alternativemodels of delivering support
or targeting support to those with poorly controlled
risk factors.
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No (%) at baseline No (%) at follow-up
Odds ratio (95% CI) P valueIntervention Control Intervention Control
HbA1c >7% 76/187 (41) 87/201 (43) 71/165 (43) 72/170 (42) 1.84 (0.60 to 5.59) 0.28
Systolic BP >130 mm Hg 143/192 (74) 148/202 (73) 87/166 (52) 103/169 (61) 0.43 (0.15 to 1.17) 0.09
Cholesterol >4.8 mmol/L 30/186 (16) 59/201 (29) 25/164 (15) 42/170 (24) 0.25 (0.05 to 1.34) 0.09
WHAT IS ALREADY KNOWN ON THIS TOPIC
Peer support could be a promising approach for diabetes care as it harnesses the ability of
patients with diabetes to support each other in managing their everyday lives
There is limited evidence to date supporting its effectiveness
WHAT THIS STUDY ADDS
Though peer support group meetings can be introduced in general practice settings, many
patients were not interested in participating, and 18% of those who agreed to participate
never attended any meetings
There was a trend towards improvements in clinical care but no significant improvements in
diabetes or psychosocial outcomes
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